366
Participants
Start Date
May 31, 2007
Primary Completion Date
December 31, 2016
Study Completion Date
May 31, 2017
Dasatinib
oral agent, continuous dosing, Cycles = 28 days
University of Pittsburgh Cancer Institute, Pittsburgh
Pennsylvania Oncology Hematology Associates, Philadelphia
Fox Chase Cancer Center, Philadelphia
Washington Cancer Institute, Washington D.C.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Winship Cancer Institute at Emory University, Atlanta
Indiana University Cancer Center, Indianapolis
University of Michigan, Ann Arbor
University of Iowa Hospitals and Clinics, Iowa City
Oncology Specialists, Park Ridge
Nebraska Methodist Hospital, Omaha
Arkansas Children's Hospital, Little Rock
MD Anderson, Houston
Kootenai Cancer Center, Coeur d'Alene
Cedars-Sinai Outpatient Cancer Center, Los Angeles
Sarcoma Oncology Center, Santa Monica
City of Hope, Duarte
Stanford University, Palo Alto
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Sarcoma Alliance for Research through Collaboration
OTHER